Skip to content
OpenCapital
Get started

Ligand Pharmaceuticals LGND Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies

WSFS Financial logo
WSFS FinancialWSFS
$0.00-100%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$47.13+56.3%
KEE
Keel Infrastructure Corp. Common StockKEEL
$0.93-21.8%
Phillips 66 logo
Phillips 66PSX
$90.11+0.9%
PepsiCo logo
PepsiCoPEP
$146.60+1.9%
L3Harris Technologies logo
L3Harris TechnologiesLHX
$199.18+8.8%

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%—
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0×0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Ligand Pharmaceuticals (LGND) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $101.43 in Q1 2026.
How has Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price increased by 24.5% year-over-year, from $81.45 to $101.43.
What is the long-term trend for Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
Over 3 years (2022 to 2025), Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a 11.3% compound annual growth rate (CAGR), from $61.31 to $84.48.